5 completed, 2 unknown, 1 recruiting, 1 terminated. 9 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 9 | Completed 5, Unknown 2, Recruiting 1, Terminated 1 |
Follow lanreotide: new trials by email Literature Review of lanreotide trials Research Report on lanreotide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients Somatostatin analog - Gastroenteropancreatic Neuroendocrine Tumor | Phase 4 | Recruiting | University Hospital, Antwerp | 270 | 2023-06-28 | 2024-06-14 |
| Study of Lanreotide in Metastatic or Recurrent Grade I-II Hindgut NET Lanreotide - Neuroendocrine Tumors | Phase 4 | Unknown | Samsung Medical Center | 28 | 2017-07-05 | 2019-05-20 |
| Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients lanreotide acetate - NeuroEndocrine Tumours | Phase 4 | Completed | Ipsen | 50 | 2014-05-01 | 2019-06-07 |
| A Pilot Study of Pre- and Post-operative Use of Somatuline Depot. lanreotide - Acromegaly | Phase 4 | Terminated | Saint John's Cancer Institute | 4 | 2013-05-01 | 2021-09-30 |
| Somatuline Autogel Preference and Health Economy Study lanreotide (Autogel formulation) - Neuroendocrine Tumour With Carcinoid Symptoms | Phase 4 | Completed | Ipsen | 26 | 2008-06-01 | 2019-11-22 |
| Treatment of the Dumping Syndrome With Lanreotide Autogel® Somatuline (Lanreotide Autogel®) - Dumping Syndrome | Phase 4 | Unknown | Radboud University Medical Center | 2007-10-01 | 2007-10-12 | |
| Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR Lanreotide (Autogel formulation) - Acromegaly | Phase 4 | Completed | Ipsen | 8 | 2004-06-01 | 2019-08-16 |
| Somatuline Autogel: Acromegaly Self/Partner Injection Study Lanreotide (Autogel formulation) - Acromegaly | Phase 4 | Completed | Ipsen | 30 | 2004-02-01 | 2019-08-05 |
| Lanreotide Autogel-120 mg as First-Line Treatment of Acromegaly Lanreotide-Autogel 120 mg - Acromegaly | Phase 4 | Completed | Federico II University | 27 | 2003-01-01 | 2008-03-03 |
Acromegaly (4) · Neuroendocrine Tumors (3) · Dumping Syndrome (1) · Gastro-enteropancreatic neuroendocrine tumor (1) · Gigantism (1) · Neoplasms (1) · Pituitary Neoplasms (1)
Ipsen (4) · Federico II University (1) · Radboud University Medical Center (1) · Saint John's Cancer Institute (1) · Samsung Medical Center (1) · University Hospital, Antwerp (1)
Netherlands (2) · United Kingdom (2) · Australia (1) · Belgium (1) · Denmark (1) · Italy (1) · Norway (1) · South Korea (1) · Sweden (1) · United States (1)
Annamaria Colao, MD, PhD (1) · Daniel F Kelly, MD (1) · Marc Peeters, MD (1) · Matthew Hickling, MD (1)
PMID 11788630, PMID 15080776, PMID 15080778, PMID 15099442, PMID 15362960, PMID 15613435, PMID 15827109, PMID 16918950, PMID 17259801, PMID 17555511, PMID 17892497, PMID 19094074, PMID 27875519, PMID 35132704, PMID 40615151